DalsnaFinance › IPOs › Lycia Therapeutics › IPO
Lycia Therapeutics, Inc. completed its initial public offering on Nasdaq on October 20, 2026, pricing at $18.00 a share.
| Ticker | LYCA |
|---|---|
| Exchange | Nasdaq |
| Status | Completed |
| Listing date | October 20, 2026 |
| Offering price | $18.00 |
| Shares offered | 17,640,000 |
| Total raised | $318M |
| Sector | Biological Products, (No Diagnostic Substances) |
Lycia Therapeutics, Inc. listed on Nasdaq on 2026-10-20.
Ingested from SEC EDGAR (424B4, 8-A12B), CIK 1806540.
Lycia Therapeutics, Inc. sold 17,640,000 shares at $18.00 each on Nasdaq. Multiplied out, that is $317.5 million in gross proceeds, the figure before underwriting discounts and offering expenses, and it agrees with the $318 million total recorded for the deal.
Measured by money raised, Lycia Therapeutics, Inc. was tied for the 82nd largest (level with 1 other deal) of 458 completed IPOs with a recorded deal size that this site tracks since November 5, 2024. The median deal in the same window raised $200 million, so this one was about 1.6 times the typical size.
Among the 10 listings on Nasdaq alone, it is the 5th largest.
October 2026 saw 13 completed IPOs in the site's data; by amount raised, Lycia Therapeutics, Inc. was the largest of the 3 deals with a recorded size.
Its $18.00 offer price was tied for the 81st highest (level with 12 other listings) of the 476 listings in the window with a recorded price. A share price on its own says nothing about a company's value; it depends on how many shares exist.
Lycia Therapeutics, Inc. — quote, profile and latest news →
Source: SEC EDGAR filings for Lycia Therapeutics, Inc.. This page is general information, not investment advice.